Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257424 · ClinicalTrials.gov registry record · Phase 1
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02257424 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 50 participants.
The verdict
NCT02257424, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
Interventions
- DRUG Trametinib 2 mg daily
- DRUG hydroxychloroquine (HCQ)
- DRUG dabrafenib 150 mg orally twice a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257424
The ClinicalTrials.gov registry entry for NCT02257424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trametinib 2 mg daily is the first listed.
NCT02257424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02257424 about?
NCT02257424 is a clinical study titled "Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma". The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.
What is the current status of trial NCT02257424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-10. Estimated completion is 2021-10.
What interventions are being tested in trial NCT02257424?
The interventions under investigation include: Trametinib 2 mg daily (DRUG), hydroxychloroquine (HCQ) (DRUG), dabrafenib 150 mg orally twice a day (DRUG).
Who is sponsoring clinical trial NCT02257424?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.